Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 2061-2070 Newer>

The Motley Fool June 7, 2005 Brian Gorman	Covance Under Fire The contract research company could suffer at the hands of the animal-rights group PETA. The value of a company's public image is hard to quantify. For investors, this is definitely a case worth watching.
BusinessWeek June 13, 2005 Timothy J. Mullaney	Hunting For Hospitals That Measure Up New Web sites can help you become an educated health-care consumer
The Motley Fool June 6, 2005 Stephen D. Simpson	"Bad News" for Teva? Yawn... Be ready to act when the market overreacts. For those investors who think that Teva Pharmaceutical will maintain its top-dog status in the generics world, this is just a blip on the scope and/or the opportunity to build a position.
The Motley Fool June 6, 2005 Stephen D. Simpson	Bristol-Myers' Paltry Penalty A reported settlement with the DOJ will put an end to an ugly scandal at the pharmaceutical, but the fine doesn't seem to fit the crime. As is always the case, the current shareholders will pay for the sins of past management.
The Motley Fool June 6, 2005 Rich Duprey	Flamel Inflames Passions The nanotech firm faces a fiery shareholder fight. Is Flamel doing enough to promote its medical technologies? Management says yes, but shareholders disagree. Here's a survey of the battlefield.
The Motley Fool June 3, 2005 Rich Duprey	Cantel Is Dealt an Olympic Blow The termination of a distribution agreement knocks the medical equipment company down 40%.
The Motley Fool June 3, 2005 Brian Gorman	Merck's New Innovation Pending FDA approval, the company's experimental shingles vaccine will probably be a steady earner. In the near term, the stock isn't going to see huge gains, but the company is here to stay and will keep innovating.
Inc. June 2005 Michelle Leder	Obesity Whets VC Appetites Anti-obesity companies are the flavor of the month among venture capitalists.
BusinessWeek June 13, 2005 Catherine Arnst	Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins.
BusinessWeek June 13, 2005 Arlene Weintraub	Why Biotech Stocks Are Sedated Biotech might seem like a can't-miss investing opportunity but many investors are taking a pass on biotech, even amid bona fide scientific advances.
<Older 2061-2070 Newer> Return to current articles.